ESMO: Novel Checkpoint Inhibitors From Merck And BMS Show Promise
Patients Progressing On PD-1/PD-L1s Need Options
TIGIT is not the only novel IO mechanism showing promise, with market leaders Merck and BMS showcasing data from other early stage combinations with Opdivo and Keytruda, while Servier presented a possible three-way combo.
